Combination of escitalopram and a 5-HT1A receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT2C receptor stimulation; Suggestive of antipsychotic potential

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 3, 2011, Pages 479-485

  Hovelsø, Nanna ^a   Sager, Thomas Nicolaj ^a   Mørk, Arne ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

5 HT2C receptor antipsychotic; Conditioned avoidance response behaviour; Dopamine; Escitalopram; Microdialysis; Nucleus accumbens; SB242084; Striatum; WAY 100635

Indexed keywords

DOPAMINE; ESCITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PINDOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN 2C RECEPTOR; VABICASERIN;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONDITIONED REFLEX; CORPUS STRIATUM; DRUG INHIBITION; DRUG MECHANISM; LIMBIC SYSTEM; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CITALOPRAM; CORPUS STRIATUM; DOPAMINE; MALE; NUCLEUS ACCUMBENS; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

RATTUS;

EID: 78149304789     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.10.003     Document Type: Article

References (55)

1. K.D. Alex, and E.A. Pehek Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission Pharmacol Ther 113 2007 296 320 (Pubitemid 46149046)
2. J. Arnt Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade Acta Pharmacol Toxicol 51 1982 321 329 (Copenh) (Pubitemid 12006638)
3. J. Arnt, T. Skarsfeldt, and J. Hyttel Differentiation of classical and novel antipsychotics using animal models Int Clin Psychopharmacol 12 Suppl 1 1997 S9 S17
4. F. Artigas, L. Romero, C. de Montigny, and P. Blier Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists Trends Neurosci 19 1996 378 383 (Pubitemid 26270513)
5. J. Ballesteros, and L.F. Callado Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials J Affect Disord 79 2004 137 147 (Pubitemid 38340537)
6. K.A. Berg, W.P. Clarke, K.A. Cunningham, and U. Spampinato Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications Neuropharmacology 55 2008 969 976
7. C.D. Blaha, and R.F. Lane Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo Neurosci Lett 78 1987 199 204 (Pubitemid 17095699)
8. P. Blier, and R. Bergeron Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression J Clin Psychopharmacol 15 1995 217 222
9. M.J. Bubar, and K.A. Cunningham Distribution of serotonin 5-HT2C receptors in the ventral tegmental area Neuroscience 146 2007 286 297 (Pubitemid 46654599)
10. C. Bundgaard, F. Larsen, M. Jørgensen, and J. Gabrielsson Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels Eur J Pharm Sci 29 2006 394 404 (Pubitemid 44780972)
11. A. Carlsson Antipsychotic drugs, neurotransmitters, and schizophrenia Am J Psychiatry 135 1978 165 173
12. A. Carlsson, N. Waters, S. Holm-Waters, J. Tedroff, M. Nilsson, and M.L. Carlsson Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence Annu Rev Pharmacol Toxicol 41 2001 237 260 (Pubitemid 32385889)
13. D.A. Clemett, T. Punhani, M.S. Duxon, T.P. Blackburn, and K.C. Fone Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS Neuropharmacology 39 2000 123 132
14. T.I. Cremers, P. de Boer, Y. Liao, F.J. Bosker, J.A. den Boer, and B.H. Westerink Augmentation with a 5-HT(1A), but not a 5-HT(1B) receptor antagonist critically depends on the dose of citalopram Eur J Pharmacol 397 2000 63 74 (Pubitemid 30323812)
15. T.I. Cremers, L.J. Wiersma, F.J. Bosker, J.A. den Boer, B.H. Westerink, and H.V. Wikstrom Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol Psychiatry 50 2001 13 21 (Pubitemid 32701989)
16. G. di Giovanni, V. di Matteo, M. di Mascio, and E. Esposito Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2 C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study Synapse 35 2000 53 61
17. E. Dremencov, M. El Mansari, and P. Blier Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area J Psychiatry Neurosci 34 2009 223 229
18. J. Dunlop, K.L. Marquis, H.K. Lim, L. Leung, J. Kao, and C. Cheesman Pharmacological profile of the 5-HT(2 C) receptor agonist WAY-163909; therapeutic potential in multiple indications CNS Drug Rev 12 2006 167 177 (Pubitemid 46047786)
19. J. Dunlop, J. Zhang, S. Watts, S. Ramamoorthy, B. Harrison, and J.E. Barret In vitro pharmacological profile of SCA-136, a novel 5-HT2C receptor selective agonist 36th Annual Meeting for the Society of Neuroscience Oct 14-18 2006 Society for Neuroscience Atlanta, GA. Washington, D.C.
20. K. Eberle-Wang, Z. Mikeladze, K. Uryu, and M.F. Chesselet Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats J Comp Neurol 384 1997 233 247 (Pubitemid 27282041)
21. A. Eltayb, M.L. Wadenberg, B. Schilström, and T.H. Svensson Antipsychotic-like effect by combined treatment with citalopram and WAY 100635: involvement of the 5-HT2C receptor Int J Neuropsychopharmacol 10 2007 405 410 (Pubitemid 46701008)
22. J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 2000 1371 1376 (Clinical research ed.)
23. M.A. Geyer, and B. Ellenbroek Animal behavior models of the mechanisms underlying antipsychotic atypicality Prog Neuropsychopharmacol Biol Psychiatry 27 2003 1071 1079 (Pubitemid 37464953)
24. S.M. Grauer, R. Graf, R. Navarra, A. Sung, S.F. Logue, and G. Stack WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics Psychopharmacology (Berl) 204 2009 37 48
25. J.A. Gray, and B.L. Roth The pipeline and future of drug development in schizophrenia Mol Psychiatry 12 2007 904 922 (Pubitemid 47482704)
26. P. Hertel, G.G. Nomikos, M. Iurlo, and T.H. Svensson Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain Psychopharmacology (Berl) 124 1996 74 86 (Pubitemid 26112776)
27. D. Hoyer, J.P. Hannon, and G.R. Martin Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol Biochem Behav 71 2002 533 554 (Pubitemid 34219205)
28. J. Ichikawa, and H.Y. Meltzer Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens J Pharmacol Exp Ther 256 1991 348 357
29. R.W. Invernizzi, M. Pierucci, E. Calcagno, G. di Giovanni, V. di Matteo, and A. Benigno Selective activation of 5-HT(2 C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study Neuroscience 144 2007 1523 1535 (Pubitemid 46138024)
30. S. Kapur, and G. Remington Serotonin-dopamine interaction and its relevance to schizophrenia Am J Psychiatry 153 1996 466 476 (Pubitemid 26113309)
31. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis Am J Psychiatry 158 2001 360 369 (Pubitemid 32205190)
32. T. Kuroki, H.Y. Meltzer, and J. Ichikawa Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens J Pharmacol Exp Ther 288 1999 774 781 (Pubitemid 29119694)
33. U.E. Lang, I. Puls, D.J. Muller, N. Strutz-Seebohm, and J. Gallinat Molecular mechanisms of schizophrenia Cell Physiol Biochem 20 2007 687 702 (Pubitemid 350059714)
34. K. Leuner, and W.E. Muller The complexity of the dopaminergic synapses and their modulation by antipsychotics Pharmacopsychiatry 39 Suppl 1 2006 S15 S20
35. J.E. Leysen 5-HT2 receptors Curr Drug Targets CNS Neurol Disord 3 2004 11 26
36. J.E. Leysen, P.M. Janssen, A. Schotte, W.H. Luyten, and A.A. Megens Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors Psychopharmacology (Berl) 112 1993 S40 S54
37. K.L. Marquis, A.L. Sabb, S.F. Logue, J.A. Brennan, M.J. Piesla, and T.A. Comery WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH- cyclopenta-[b][1, 4]diazepino[ 6, 7, 1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity J Pharmacol Exp Ther 320 2007 486 496 (Pubitemid 46025760)
38. A. Mørk, L.M. Witten, and J. Arnt Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved Psychopharmacology (Berl) 206 2009 39 49
39. K.T. Mueser, and S.R. McGurk Schizophrenia Lancet 363 2004 2063 2072 (Pubitemid 38781110)
40. H. Mulder, D. Cohen, H. Scheffer, W.C. Gispen-de, J. Arends, and F.W. Wilmink HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study J Clin Pychopharmacol 29 2009 16 20
41. C.P. Muller, R.J. Carey, G. Jocham, and J.P. Huston Cocaine increases serotonergic activity in the hippocampus and nucleus accumbens in vivo: 5-HT1a-receptor antagonism blocks behavioral but potentiates serotonergic activation Synapse 45 2002 67 77 (Pubitemid 34742942)
42. S. Navailles, D. Moison, K.A. Cunningham, and U. Spampinato Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine Neuropsychopharmacology 33 2008 237 246 (Pubitemid 350243355)
43. A. Newman-Tancredi, C. Chaput, S. Gavaudan, L. Verriele, and M.J. Millan Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors Neuropsychopharmacology 18 1998 395 398 (Pubitemid 28140665)
44. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 2007 Academic Press New York
45. R.H. Porter, K.R. Benwell, H. Lamb, C.S. Malcolm, N.H. Allen, and D.F. Revell Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells Br J Pharmacol 128 1999 13 20 (Pubitemid 29425262)
46. L. Pozzi, S. Acconcia, I. Ceglia, R.W. Invernizzi, and R. Samanin Stimulation of 5-hydroxytryptamine (5-HT(2C) ) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex J Neurochem 82 2002 93 100 (Pubitemid 34755253)
47. S. Prisco, S. Pagannone, and E. Esposito Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo J Pharmacol Exp Ther 271 1994 83 90 (Pubitemid 24333116)
48. N. Rao The clinical pharmacokinetics of escitalopram Clin Pharmacokinet 46 2007 281 290 (Pubitemid 46507007)
49. G. Remington Understanding antipsychotic "atypicality": a clinical and pharmacological moving target J Psychiatry Neurosci 28 2003 275 284 (Pubitemid 37153435)
50. G.P. Reynolds, L.A. Templeman, and Z.J. Zhang The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment Prog Neuropsychopharmacol Biol Psychiatry 29 2005 1021 1028 (Pubitemid 41080129)
51. S. Rosenzweig-Lipson, J. Dunlop, and K.L. Marquis 5-HT2C receptor agonists as an innovative approach for psychiatric disorders Drug News Perspect 20 2007 565 571 (Pubitemid 351480207)
52. J.A. Siuciak, D.S. Chapin, S.A. McCarthy, V. Guanowsky, J. Brown, and P. Chiang CP-809, 101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 52 2007 279 290 (Pubitemid 46123348)
53. D.A. Wacker, and K.J. Miller Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases Curr Opin Drug Discovery Dev 11 2008 438 445 (Pubitemid 351950839)
54. M.L. Wadenberg, and P.B. Hicks The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23 1999 851 862 (Pubitemid 29458891)
55. J.Y. Zhang, D.M. Kowal, S.P. Nawoschik, Z. Lou, and J. Dunlop Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms Biochem Pharmacol 71 2006 521 529 (Pubitemid 43077085)